chapter  19
16 Pages

Use of HBOC-201 as an Oxygen Therapeutic in the Preclinical and Clinical Settings

For several decades a wide variety of strategies have been investigated for the

replacement of stored red blood cells (RBCs) by “blood substitutes.” Currently

the most common method is the use of volume expanders, such as hetastarch,

but this does not directly address tissue oxygen requirements. Purified hemo­

globin solutions, both encapsulated and acellular, and perfiuorocarbons have

been developed to deliver oxygen. Hemoglobin-based oxygen carriers

(HBOCs), which are made from acellular hemoglobin, are close to commercial­

ization because of the combination of their ability to transport a large amount

of oxygen when compared to perfiuorocarbons and their relative ease of pro­

duction when compared to encapsulated hemoglobin. With the emergence of

sophisticated purification technologies and understanding of the modifications

necessary to eliminate side effects, great strides have recently been made in the

field. Furthermore, pharmacological and physiological studies have identified a

more efficient oxygen therapy role for HBOCs compared to RBC hemoglobin.